Becton, Dickinson & Aktie News

FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").

Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 Non-GAAP EPS and $5.25B revenue, surpassing expectations. BDX completed the spin-off of its Life Sciences & Diagnostic Solutions segment, receiving $4B to be split between debt reduction and share repurchases. Management reaffirmed FY26 guidance, projecting low single-digit revenue growth and established adjusted EPS of...

Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript

Medical device maker Becton Dickinson cut its profit forecast for fiscal year 2026 on Monday, adjusting its outlook to account for the separation and sale of its biosciences and diagnostics unit to lab equipment manufacturer Waters.

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE: WAT).

Announces appointment of Claire M. Fraser, Ph.D.

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close today Company affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BD FRANKLIN LAKES, N.J., Feb. 9,...

Dividend Aristocrats underperformed the S&P 500 in 2025, with NOBL returning 6.82% versus SPY's 17.70%. 2026 began strong for Aristocrats, with NOBL gaining 5.67% in January, outpacing SPY's 1.47%. Dividend growth for Aristocrats averaged 5.52% in 2025, but early 2026 increases trend slightly lower, raising questions for the year's outlook.